MCID: GST050
MIFTS: 57

Gastrointestinal System Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Disease

MalaCards integrated aliases for Gastrointestinal System Disease:

Name: Gastrointestinal System Disease 12 15
Gastrointestinal Diseases 55 72
Gastrointestinal Disorders 15
Digestive System Disorders 72
Alimentary System Disease 12
Digestive System Disorder 12
Gastrointestinal Disorder 12
Digestive System Diseases 44
Gastrointestinal Disease 12
Digestive System Disease 17
Gastroenteropathy 12
Git Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:77
ICD9CM 35 520-579.99
MeSH 44 D004066
SNOMED-CT 68 53619000
ICD10 33 11 K92.8 K92.9
UMLS 72 C0012242 C0017178

Summaries for Gastrointestinal System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in the gastrointestinal tract.

MalaCards based summary : Gastrointestinal System Disease, also known as gastrointestinal diseases, is related to gallbladder disease and stomach disease, and has symptoms including nausea and vomiting, constipation and vomiting. An important gene associated with Gastrointestinal System Disease is CCK (Cholecystokinin), and among its related pathways/superpathways are MicroRNAs in cancer and Immune response_Oncostatin M signaling via JAK-Stat in human cells. The drugs Indomethacin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon.

Wikipedia : 75 Gastrointestinal diseases (abbrev. GI diseases or GI illnesses) refer to diseases involving the... more...

Related Diseases for Gastrointestinal System Disease

Diseases related to Gastrointestinal System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 903)
# Related Disease Score Top Affiliating Genes
1 gallbladder disease 33.0 MLN CCKAR CCK
2 stomach disease 33.0 S100A8 MLN GHRL GAST ATP4A
3 pancreas disease 31.8 GCG GAST CCK
4 dyspepsia 31.7 GHRL CCKAR CCK
5 atrophic gastritis 31.6 S100A8 GHRL GAST
6 gastroparesis 31.5 MLN GHRL GAST CCK
7 pancreatic cancer 31.4 MIR21 MIR199A1 MIR143 GAST CCKAR CCK
8 duodenitis 31.3 GAST ATP4A
9 granulomatous gastritis 31.3 GAST ATP4A
10 duodenal ulcer 31.2 S100A8 GAST CCK
11 gastritis 31.2 S100A8 GHRL GAST
12 irritable bowel syndrome 31.2 MLN HTR4 CCK
13 esophagitis, eosinophilic, 1 31.1 CCL11 ATP4A
14 clostridium difficile colitis 31.1 CCR6 ATP4A
15 functional diarrhea 31.1 HTR4 GHRL ATP4A
16 constipation 31.1 MLN HTR4 GAST CCK
17 duodenogastric reflux 31.0 MLN GAST CCK
18 lymphoma, mucosa-associated lymphoid type 31.0 S100A8 MADCAM1 ATP4A
19 peptic ulcer disease 31.0 S100A8 GHRL GAST ATP4A
20 gastroesophageal reflux 31.0 MLN GHRL GCG GAST CCK
21 body mass index quantitative trait locus 11 31.0 MIR143 GHRL GCG CCKAR CCK
22 bile reflux 30.9 CCK ATP4A
23 pylorospasm 30.8 MLN HTR4 GHRL GAST
24 psoriasis 30.8 MIR31 MIR21 MIR122
25 blind loop syndrome 30.8 MLN HTR4 GHRL ATP4A
26 eosinophilic gastritis 30.8 CCL11 ATP4A
27 pancreatic ductal adenocarcinoma 30.7 MIR31 MIR21 MIR143
28 eosinophilic enteropathy 11.6
29 gastritis, familial giant hypertrophic 11.2
30 diverticulitis 11.2
31 gastrointestinal ulceration, recurrent, with dysfunctional platelets 11.2
32 hypoascorbemia 11.2
33 postcholecystectomy syndrome 11.0 MLN GAST CCK
34 pancreatic steatorrhea 11.0 GHRL CCK ATP4A
35 functional gastric disease 11.0 MLN GHRL CCK ATP4A
36 pancreatic cholera 11.0 GCG GAST CCK
37 esophagus adenocarcinoma 11.0 MIR21 MIR143 ATP4A
38 space motion sickness 11.0 MLN GAST CCK
39 peptic ulcer perforation 11.0 S100A8 GAST ATP4A
40 esophageal atresia/tracheoesophageal fistula 11.0
41 mucositis 11.0
42 diarrhea 11.0
43 mouth disease 11.0
44 intestinal disease 11.0
45 appendix disease 11.0
46 esophageal disease 11.0
47 peritonitis 11.0
48 lactase deficiency, congenital 11.0
49 gastrointestinal neuroendocrine benign tumor 11.0 GAST ATP4A
50 oral squamous cell carcinoma 11.0 MIR31 MIR21 MIR199A1 MIR143 MIR122

Graphical network of the top 20 diseases related to Gastrointestinal System Disease:



Diseases related to Gastrointestinal System Disease

Symptoms & Phenotypes for Gastrointestinal System Disease

UMLS symptoms related to Gastrointestinal System Disease:


nausea and vomiting, constipation, vomiting, abdominal pain, diarrhea, nausea, halitosis, abdominal bloating, icterus, signs and symptoms, digestive, rectal tenesmus, decrease in appetite, dyspepsia, heartburn, gastrointestinal gas, anal discomfort, oral manifestations, digestive system symptom, vomiting alone, catarrh, flatulence, eructation, and gas pain, symptoms involving digestive system, other symptoms involving digestive system, odynophagia, swallowing problems, pathological conditions, signs and symptoms, signs and symptoms of ill-defined conditions, glossalgia, gastric irritation, abdominal cramps, abdomen, acute, eructation, flatulence, rectal pain, liver tender, abdominal discomfort, upper abdominal pain, lower abdominal pain, retching, dry throat, hyperemesis, abdominal distress, epigastric pain not food-related, right upper quadrant pain, epigastric food-related pain, upset stomach, abdominal fullness, salivary gland pain, abdominal distention, gaseous, anal pain, infantile colic, vomiting in newborn, change in bowel habits, stomach cramps (finding), gastrointestinal symptoms, sore lip, gastrointestinal pain, abdominal distress/pain as reason for lower g.i. examination, abdominal distress/pain as reason for upper g.i. examination, epigastric discomfort, blood in stool, peeling tongue

Drugs & Therapeutics for Gastrointestinal System Disease

Drugs for Gastrointestinal System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 596)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
2
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
3
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
4
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
5
Amitriptyline Approved Phase 4 50-48-6 2160
6
Perphenazine Approved Phase 4 58-39-9 4748
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
10
Metronidazole Approved Phase 4 443-48-1 4173
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
13
Clarithromycin Approved Phase 4 81103-11-9 84029
14
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
15
Bisacodyl Approved Phase 4 603-50-9
16
Prucalopride Approved Phase 4 179474-81-8
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
19
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
20
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
21
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
22
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
23
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
24
Racepinephrine Approved Phase 4 329-65-7 838
25
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
26
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
27
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
28
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
29
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
30
Sodium citrate Approved, Investigational Phase 4 68-04-2
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
33
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
34
Azithromycin Approved Phase 4 83905-01-5 447043 55185
35
Ustekinumab Approved, Investigational Phase 4 815610-63-0
36
Calcium carbonate Approved, Investigational Phase 4 471-34-1
37 Vedolizumab Approved Phase 4 943609-66-3
38
Pancrelipase Approved, Investigational Phase 4 53608-75-6
39
Mycophenolic acid Approved Phase 4 24280-93-1 446541
40
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
41
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
42
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
43
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
44
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46 Tocotrienol Investigational Phase 4 6829-55-6
47
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
48 Neurotransmitter Agents Phase 4
49 Pharmaceutical Solutions Phase 4
50 Anesthetics, Intravenous Phase 4

Interventional clinical trials:

(show top 50) (show all 842)
# Name Status NCT ID Phase Drugs
1 The Treatment of Periodontal Diseases. A Randomized, Blinded, Five Years Follow-up, Four-arm, Placebo Controlled Clinical Intervention Trial Unknown status NCT01318928 Phase 4 Metronidazol
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Oral Resveratrol Before ERCP Redused Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
4 Phase 4 Study of Helicobacter Pylori Eradication Therapy Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
5 EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS Unknown status NCT02241876 Phase 4 N-acetylcysteine
6 Randomized Controlled Trial Testing the Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old Unknown status NCT02430831 Phase 4
7 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
8 Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial Completed NCT01495806 Phase 4 Glucomannan;placebo
9 Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study. Completed NCT00424905 Phase 4 Bacillus clausii
10 Comparison of the Eradication Rate Between 1- and 2-Week PPI Containing Therapies for Helicobacter Pylori Eradication Completed NCT02487511 Phase 4
11 Evaluation of the Efficacy of Amitriptyline in Children With Abdominal Pain of Non-Organic Origin Completed NCT00564525 Phase 4 Amitriptyline;Placebo
12 A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
13 Clinical Use of an Absorbable Coated Suture Material in Surgery (Safil) One Layer Running(A) vs. Two-Layer Suture Technique (B) Completed NCT00645684 Phase 4
14 A Randomised, Multicentre, Single-Blind, Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation. Completed NCT00605228 Phase 4 MOVIPREP;COLOPEG
15 Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Raperazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fed Conditions Completed NCT02605395 Phase 4 IDIAZOLE 20mg DR tabs;PARIET 20 mg DR tabs
16 Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt)and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions Completed NCT02446483 Phase 4 Idiazole 20mg DR tabs;PARIET 20 mg DR tabs
17 The Effects of Fentanyl and Alfentanil as an Adjunct to Propofol on Cognitive Functions for Sedation in Colonoscopy Completed NCT02267681 Phase 4 Fentanyl;Alfentanil;Propofol
18 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
19 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
20 Assistance Robotics for the Surgical Treatment of the Abdominal Wall Hernia Completed NCT00908193 Phase 4
21 The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Completed NCT02726295 Phase 4 E. coli Nissle 1917(Mutaflor®);Placebo
22 The Effect of Esomeprazole (Nexium) on the Incidence and Severity of Gastrointestinal Adverse Events Associated With a Colonoscopy Purgative Completed NCT00225238 Phase 4 esomeprazole (PPI)
23 Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children. A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01595932 Phase 4
24 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder Completed NCT00401258 Phase 4 duloxetine
25 Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention Completed NCT00860236 Phase 4
26 An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection Completed NCT00216450 Phase 4 rabeprazole sodium
27 The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus Completed NCT01911663 Phase 4
28 Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression Completed NCT00306397 Phase 4 Rapamycin
29 Comparison of the I-gel Laryngeal Mask and the Classic Laryngeal Mask in Patients With a BMI>25 During Elective Surgery Completed NCT01003327 Phase 4
30 An Open-label, Randomised, Crossover, Reader Blinded, Study to Compare the Effect of Polyethylene Glycol 3350, Bisacodyl and Prucalopride on Colonic Motility Assessed With Intraluminal Colonic Manometry in Healthy Subjects Completed NCT03279341 Phase 4 polyethylene glycol;Bisacodyl;Prucalopride
31 Metronidazole for the Treatment of Dientamoebiasis in Children in Denmark - A Randomized, Placebo-controlled, Double-blinded Clinical Trial Completed NCT01314976 Phase 4 Metronidazole;Placebo
32 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
33 Short Protocol Barostat for Assessment of Anorectal Function Versus Standard Protocol Barostat in Healthy Volunteers Completed NCT01456442 Phase 4
34 Absorption of Orally Ingested Phosphate in Head and Neck Cancer Patients With and Without Refeeding Syndrome Completed NCT02880072 Phase 4
35 Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD) Completed NCT02805907 Phase 4 Calcifediol;Placebo
36 Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study Completed NCT00247338 Phase 4 low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
37 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
38 Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia Completed NCT01349413 Phase 4 Esomeprazole 20mg
39 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
40 Protective Effects of Probiotic Administration on SIBO Development and Bowel Symptom Onset in GERD Patients at Long-term PPI Treatment: a Randomized Controlled Cross-sectional Study Completed NCT02054455 Phase 4
41 Propolis Improves Periodontal Status and Glycemic Control in Subjects With Type 2 Diabetes Mellitus and Chronic Periodontitis: a Randomized Clinical Trial Completed NCT02794506 Phase 4 Propolis;Placebo
42 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
43 Opioid Free Versus Opioid Balanced Anesthesia in Middle Ear Surgery. Completed NCT03809949 Phase 4 Fentanyl Opioid anesthesia;Saline Nonopioid anesthesia
44 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
45 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
46 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Recruiting NCT02764671 Phase 4
47 Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation Recruiting NCT02974686 Phase 4 Everolimus;Mycophenolic Acid
48 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
49 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Recruiting NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
50 Prebiotic Treatment in People With Schizophrenia Recruiting NCT03617783 Phase 4 Prebiotin;Placebo

Search NIH Clinical Center for Gastrointestinal System Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Belladonna Alkaloids
belladonna extract, USP
BELLADONNA LEAF
Dicyclomine
Dicyclomine Hydrochloride
Domperidone
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR
Sacrosidase

Cochrane evidence based reviews: digestive system diseases

Genetic Tests for Gastrointestinal System Disease

Anatomical Context for Gastrointestinal System Disease

MalaCards organs/tissues related to Gastrointestinal System Disease:

41
Testes, Liver, Colon, Small Intestine, Pancreas, Bone, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Disease:

19
Gastrointestinal Tract

Publications for Gastrointestinal System Disease

Articles related to Gastrointestinal System Disease:

(show top 50) (show all 4421)
# Title Authors PMID Year
1
The vanilloid receptor TRPV1: role in cardiovascular and gastrointestinal protection. 9 38
19879868 2010
2
Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications (review). 9 38
19885611 2009
3
Lactoferrin in gastrointestinal disease. 9 38
19652425 2009
4
Application of ghrelin to gastrointestinal diseases. 9 38
18821473 2008
5
Cholecystokinin. 9 38
17940422 2007
6
Prevalence of Helicobacter pylori cagA, iceA and babA2 alleles in Brazilian patients with upper gastrointestinal diseases. 9 38
17181989 2006
7
Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. 9 38
16937534 2006
8
Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. 9 38
16364500 2006
9
Circulating ghrelin levels in patients with various upper gastrointestinal diseases. 9 38
15906753 2005
10
Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. 9 38
16259736 2005
11
Topographical localisation of cagA positive and cagA negative Helicobacter pylori strains in the gastric mucosa; an in situ hybridisation study. 9 38
15280402 2004
12
T helper-2 immunity regulates bronchial hyperresponsiveness in eosinophil-associated gastrointestinal disease in mice. 9 38
15236177 2004
13
cagA and vacA genotype of Helicobacter pylori associated with gastric diseases in Xi'an area. 9 38
12918116 2003
14
Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. 9 38
12688377 2002
15
Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. 9 38
12168865 2002
16
[Helicobacter pylori genotypes in non atrophic gastritis are different of the found in peptic ulcer, premalignant lesions and gastric cancer in Colombia]. 9 38
11974526 2002
17
ALX-0600 (NPS Allelix Corp). 9 38
11566007 2001
18
Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. 9 38
10710054 2000
19
Direct determination of Helicobacter pylori vacA genotypes and cagA gene in gastric biopsies and relationship to gastrointestinal diseases. 9 38
10364019 1999
20
High frequency of cytotoxin-associated gene A in Helicobacter pylori isolated from asymptomatic subjects and peptic ulcer patients in Taiwan. 9 38
9706771 1998
21
[Measurement of fecal lactoferrin for diagnosis on pediatric gastrointestinal disease]. 9 38
9437905 1997
22
A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700. 9 38
8704058 1996
23
Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCKAR and CCKBR) in human and mouse. 9 38
7759110 1995
24
Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini. 9 38
1995267 1991
25
Fecal isoamylase activity in patients with pancreatic diseases. 9 38
1704633 1991
26
Maintenance of Intestinal Epithelial Homeostasis by Zinc Transporters. 38
30830525 2019
27
Onion bulb extract reduces colitis severity in mice via modulation of colonic inflammatory pathways and the apoptotic machinery. 38
31158441 2019
28
Gut organoids: mini-tissues in culture to study intestinal physiology and disease. 38
31216420 2019
29
Assessment of the first commercial multiplex PCR kit (ParaGENIE Crypto-Micro Real-Time PCR) for the detection of Cryptosporidium spp., Enterocytozoon bieneusi, and Encephalitozoon intestinalis from fecal samples. 38
31079868 2019
30
Agave salmiana fructans as gut health promoters: Prebiotic activity and inflammatory response in Wistar healthy rats. 38
31189087 2019
31
Characterization of Candidemia in Patients with Recent Surgery: A 7-Year Experience. 38
31421007 2019
32
The role of gut microbiota for the activity of medicinal plants traditionally used in the European Union for gastrointestinal disorders. 38
31408679 2019
33
Endoscopic Ultrasound in Pediatric Patients With Pancreatobiliary Disease. 38
31259867 2019
34
Cilostazol against 2,4,6-trinitrobenzene sulfonic acid-induced colitis: Effect on tight junction, inflammation, and apoptosis. 38
31406920 2019
35
Vagus Nerve Stimulation at the Interface of Brain-Gut Interactions. 38
30201788 2019
36
In Vivo Quantitative Photoacoustic Diagnosis of Gastric and Intestinal Dysfunctions with a Broad pH-Responsive Sensor. 38
31361949 2019
37
8-methoxysmyrindiol from Gerbera piloselloides (L.) Cass. and its vasodilation effects on isolated rat mesenteric arteries. 38
31404616 2019
38
Probiotics Upregulate Trefoil Factors and Downregulate Pepsinogen in the Mouse Stomach. 38
31405107 2019
39
Diagnostic Workup and Micronutrient Deficiencies in Children With Failure to Thrive Without Underlying Diseases. 38
30644589 2019
40
Spatial distribution characteristics of tumor marker CA724 reference values in China. 38
31199587 2019
41
Survival of probiotic bacteria in the presence of food grade nanoparticles from chocolates: an in vitro and in vivo study. 38
31201450 2019
42
Association between major depressive disorder and multiple disease outcomes: a phenome-wide Mendelian randomisation study in the UK Biobank. 38
31427754 2019
43
Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases. 38
31435165 2019
44
Molecular epidemiology of human bocavirus in children with acute gastroenteritis from North Region of Brazil. 38
31215861 2019
45
The role of fecal calprotectin in pediatric disease. 38
30999729 2019
46
Forsythia suspensa Protects against Bone Loss in Ovariectomized Mice. 38
31398803 2019
47
Exosomes as a novel cell-free therapeutic approach in gastrointestinal diseases. 38
30536895 2019
48
Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. 38
30873652 2019
49
Subacute combined degeneration of the spinal cord is associated with tripterygium glycoside tablet usage. 38
30903417 2019
50
Artificial Intelligence-Based Classification of Multiple Gastrointestinal Diseases Using Endoscopy Videos for Clinical Diagnosis. 38
31284687 2019

Variations for Gastrointestinal System Disease

Expression for Gastrointestinal System Disease

Search GEO for disease gene expression data for Gastrointestinal System Disease.

Pathways for Gastrointestinal System Disease

Pathways related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 MIR31 MIR21 MIR199A1 MIR17 MIR143 MIR122
2 10.54 SERPINA3 CCL11
3 10 GAST CCK
4 9.65 GAST ATP4A

GO Terms for Gastrointestinal System Disease

Cellular components related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.47 SERPINA3 S100A8 MIR31 MIR21 MIR199A1 MIR17
2 secretory granule lumen GO:0034774 9.26 SERPINA3 S100A8 GHRL GCG

Biological processes related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.7 MIR21 MIR143 GHRL
2 miRNA mediated inhibition of translation GO:0035278 9.65 MIR31 MIR21 MIR17
3 positive regulation of sprouting angiogenesis GO:1903672 9.56 MIR31 GHRL
4 positive regulation of angiogenesis GO:0045766 9.56 MIR31 MIR21 MIR143 CCL11
5 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.55 MIR21 MIR143
6 positive regulation of vascular endothelial cell proliferation GO:1905564 9.54 MIR21 GHRL
7 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.51 MIR21 MIR17
8 gene silencing by miRNA GO:0035195 9.5 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR143
9 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.46 MIR199A1 MIR17
10 positive regulation of metalloendopeptidase activity GO:1904685 9.43 MIR21 MIR17
11 leukocyte migration involved in inflammatory response GO:0002523 9.4 S100A8 CCR6
12 chronic inflammatory response GO:0002544 9.37 S100A8 CCL11
13 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.32 MIR21 MIR17
14 G protein-coupled receptor signaling pathway GO:0007186 9.28 MLN HTR4 GHRL GCG GAST CCR6
15 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.16 MIR17 MIR143
16 signal transduction GO:0007165 10.04 MADCAM1 HTR4 GAST CCR6 CCL11 CCKAR

Molecular functions related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.35 MLN GHRL GCG GAST CCK
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR143

Sources for Gastrointestinal System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....